What the FDA labels say about taking them together
Meloxicam and methotrexate
Meloxicam's FDA label (Qamzova) of July 16, 2026 names methotrexate in its drug interactions section; methotrexate's label does not name meloxicam itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The meloxicam label: “Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity.”
Check it at the source: the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.); the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.).
What does the meloxicam label say about methotrexate?
Qamzova label (Nanjing Delova Biotech Co., Ltd., July 16, 2026), drug interactionsMethotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (…). Intervention: During concomitant use of QAMZOVA and methotrexate, monitor patients for methotrexate toxicity.
Meloxicam label (Emerald Therapeutics, LLC, May 29, 2026), drug interactionsClinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (…). Intervention: During concomitant use of meloxicam oral suspension and methotrexate, monitor patients for methotrexate toxicity.
Source: FDA drug label (Qamzova, NDA217593), Nanjing Delova Biotech Co., Ltd., effective July 16, 2026 (SPL set 385fd779-1be1-49ae-8213-750b96ecc997), via openFDA
Source: FDA drug label (Xifyrm, NDA218395), Azurity Pharmaceuticals, Inc., effective June 18, 2025 (SPL set bf2b198c-0726-488a-b911-4fe394e4b56e), via openFDA
Source: FDA drug label (Meloxicam, NDA021530), Emerald Therapeutics, LLC, effective May 29, 2026 (SPL set 55af77dd-2abc-49a6-990c-399d5a5e7a91), via openFDA
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
What does the methotrexate label say about meloxicam?
Methotrexate's label does not name meloxicam itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Methotrexate label, boxed warningUnexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs) [see Warnings and Precautions (5.1) and Drug Interactions(7.1) ].
Methotrexate label, drug interactionsConcomitant administration of some NSAIDs with high dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity [see Warnings and Precautions (5.1) ].
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Meloxicam | Methotrexate | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain | Rheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0166 per tablet 7.5 mg tablet | $0.158 per tablet 2.5 mg tablet |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once